229. 肺胞蛋白症(自己免疫性又は先天性) Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details


臨床試験数 : 43 薬物数 : 34 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01842386
(ClinicalTrials.gov)
April 29, 201425/4/2013Rituximab for Anti-cytokine Autoantibody-Associated DiseasesRituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated DiseasesPulmonary Alveolar Proteinosis (PAP);Severe Mucocutaneous CandidiasisDrug: RituximabNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 YearsN/AAll7Phase 1United States
2NCT00552461
(ClinicalTrials.gov)
January 200731/10/2007Prospective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisProspective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisPulmonary Alveolar Proteinosis;Primary DiseaseDrug: rituximabEast Carolina UniversityGenentech, Inc.Recruiting18 YearsN/ABoth10Phase 2United States